Merck and AbbVie face bipartisan congressional investigations into clinical trials at Chinese military linked facilities. Here is what the probes mean alongside each stock's price, valuation and dividend data.
Merck and AbbVie are facing congressional scrutiny over clinical trials conducted at Chinese facilities, including sites tied to the country's military, after a bipartisan group of lawmakers opened national security investigations into both drugmakers this week. The probes, led by the House Select Committee on China, could add a layer of uncertainty to two stocks that income investors have long favored for their dividends and steady earnings.
At a Glance
- Rep. John Moolenaar's committee sent letters demanding information by July 17
- Merck linked to 224 China based clinical studies since 2005, including 31 in Xinjiang
- AbbVie tied to over 100 studies since 2007, with 17 in Xinjiang
- Neither company is accused of breaking any laws
- China's share of early stage global drug development rose from 8% in 2015 to over 32% in 2024
What Triggered the Investigations
Letters dated Monday and addressed to Merck chief executive Robert Davis and AbbVie chief executive Robert Michael ask both firms to explain how they select trial sites, safeguard patient data and maintain safety oversight. The committee singled out facilities in Xinjiang and hospitals connected to China's military, warning that research conducted at PRC military hospitals could expose American biotechnology intellectual property to transfer risk.
Committee findings show Merck's China trial footprint includes 40 studies at military linked facilities, while AbbVie's includes 16. Lawmakers also referenced Xinjiang's status as the site of what they call genocide against Uyghur and other minority populations, along with documented cases of Chinese researchers failing to secure proper informed consent from participants.
Merck responded that patient safety and ethical conduct remain central to its research program and that it adheres to global regulatory standards. AbbVie did not comment directly on the investigation. A spokesperson for China's embassy in Washington dismissed the committee's claims as lacking credibility and accused U.S. officials of politicizing trade and technology matters.
What the Numbers Say
Merck shares carry a price to earnings ratio that reflects a mature pharmaceutical name trading well below the broader market's growth multiples, with earnings per share supported by its oncology and vaccine franchises even as Gardasil sales in China have softened. AbbVie, meanwhile, has leaned on Skyrizi and Rinvoq to offset the biosimilar erosion hitting Humira, its former blockbuster, and that shift has kept revenue growth intact despite the patent cliff.
Both companies remain fixtures among dividend paying healthcare stocks, with yields that continue to attract income focused investors even as headline prices move on news flow like this week's congressional letters. Relative strength readings for both names sit in neutral territory, suggesting the market has not yet priced in a dramatic shift in sentiment, though any escalation in the investigation, particularly a finding tied to intellectual property leakage, could pressure momentum further. Valuation multiples for both stocks remain modest compared to high growth biotech peers, a reflection of their status as established, cash generative businesses rather than speculative growth stories.
The bull case rests on diversified drug portfolios, consistent dividend payouts and the fact that neither company has been accused of illegal conduct. The bear case centers on regulatory risk under the Biosecure Act, reputational exposure tied to Xinjiang research sites and the broader trend of China capturing a growing share of global drug development, up from 8% to over 32% between 2015 and 2024 while the U.S. share fell from 48% to roughly 37%.
Frequently Asked Questions
Are Merck and AbbVie accused of breaking any laws?
No. The congressional letters explicitly state that neither company is known to have violated any laws, though lawmakers raised ethical and national security concerns about their China based trial activity.
What is the Biosecure Act?
Signed into law by President Trump last year, the Biosecure Act restricts federal agencies from doing business with certain non U.S. biotechnology companies, part of a broader push to limit China's influence in the biotech supply chain.
What deadline did lawmakers set for the companies to respond?
The letters, dated Monday, ask Merck and AbbVie to submit detailed information about their clinical trial oversight practices by July 17.
reup>Where This Leaves Investors
The investigations add a geopolitical wrinkle to two pharmaceutical giants whose stock performance has typically hinged on drug pipelines, patent expirations and dividend reliability rather than congressional scrutiny. How Merck and AbbVie respond by the July 17 deadline, and whether the committee finds anything beyond the ethical concerns already flagged, will determine whether this becomes a lasting overhang or a passing headline.
